During the period, the Company continuously augmented internal growth with strategic acquisitions—most notably the integration of life technologies into its life sciences solutions segment—and divested non-core businesses to secure antitrust approval and concentrate on core operations, thereby preserving or improving functioning under competitive and regulatory pressures. Management attributes increased operating income and cost efficiencies to its Practical Process Improvement business system, global sourcing initiatives, restructuring actions—including headcount reductions and consolidation of facilities—and low-cost region manufacturing, which together are expected to yield annual cost savings of approximately $120 million beginning in part in 2014 and enhance operational flexibility. The Company maintains a combination of cash, cash equivalents and short-term investments alongside an unsecured multi-currency revolving credit facility, deliberately leaving undrawn capacity equivalent to outstanding commercial paper to ensure continuity of funding in the event of market disruptions and to meet foreseeable cash requirements for at least the next 24 months. In its goodwill and indefinite-lived intangible asset impairment testing, management considers indicators such as unexpected adverse business conditions, competitive activities, technological changes and forecasted cash flows, recognizing that changes in future performance or discount rates could necessitate impairment charges and trigger resource reconfiguration processes. The liquidity and capital resources plan, which includes debt instruments, defined provisions for contingent considerations, letters of credit, bank guarantees, purchase obligations and indemnification provisions in divestiture agreements, underscores the Company’s proactive risk assessment, business continuity planning and commitment to maintaining system integrity under internal or external variations and disturbances. Critical accounting estimates—such as allowances for doubtful accounts, inventory obsolescence writedowns, warranty liabilities and valuation allowances for deferred tax assets—are updated based on historical experience, current market conditions and management’s judgments to support accurate financial reporting and organizational health under uncertain conditions.